News

Notre Dame Student Researcher Participates in Biomedical Entrepreneurship Crash Course

Author: Brandi Klingerman

Each year, SPARK, a Stanford University initiative that provides the education and mentorship in order to advance research discoveries from the bench to the bedside, hosts a diverse group to participate in a 12-day training course in biotech innovation and entrepreneurship. The program provides an understanding of how biotechnology products, such as medical devices, food science, and general medical science, and companies are created, established, managed, advertised, and funded. Ricardo Romero, graduate student of the Integrated Biomedical Sciences program and researcher in the Harper Cancer Research Institute, had the opportunity to attend the program through the Indiana Clinical and Translational Sciences Institute (Indiana CTSI).

Read More

Fighting to Cure Food Allergies

Author: Brandi Klingerman

Professor Basar Bilgicer hopes to make allergies, and the accompanying anxiety and trauma, a thing of the past. For an aspiration that large, he had to start small. Biomolecular small.

Read More

Notre Dame interdisciplinary researchers receive $1.1 million grant from NIH

Author: Tammi Freehling

Patricia Clark

Researchers representing four labs across two colleges at Notre Dame have received a four-year, $1.1 million Research Project Grant (R01) from the National Institute of General Medical Sciences at the National Institutes of Health (NIH). The oldest grant mechanism used by the NIH, the R01 provides support for health-related research and development based on the mission of the NIH.

Read More

Nanoparticles with a big environmental impact

Author: Brandi Klingerman

Jon Camden

Consider that a human hair is anywhere from 60,000 to 80,000 nanometers in size. A plasmonic nanoparticle, which is a nanoparticle made of noble metals like gold and silver, at their largest are just 100 nanometers, but pack a big punch.

Read More

Notre Dame researchers find transition point in semiconductor nanomaterials

Author: Gene Stowe

Collaborative research at Notre Dame has demonstrated that electronic interactions play a significant role in the dimensional crossover of semiconductor nanomaterials. The laboratory of Masaru Kuno, professor of chemistry and biochemistry, and the condensed matter theory group of Boldizsár Jankó, professor of physics, have now shown that a critical length scale marks the transition between a zero-dimensional, quantum dot and a one-dimensional nanowire.

Read More

A summer of analytical chemistry at Notre Dame

Author: Chontel Syfox

Analytical Chemistry REU Presentations 2016

This summer the University of Notre Dame welcomed twelve students to campus to participate in the NSF-funded Research Undergraduate Experience (REU) program in analytical chemistry. The 10-week residential program is open to rising sophomore, junior, and senior undergraduates at four-year colleges, with backgrounds in chemistry, biochemistry, biology, chemical engineering, computer science, and mechanical or electrical engineering. It offers students the opportunity to work with Notre Dame faculty on various research projects aimed at solving analytical problems in the developing world, and “teaches students how to engage with a project at the instrumental and experimental design level.” 

Read More

Steve Corcelli named ACS Fellow

Author: Marissa Gebhard

Steven Corcelli Named ACS Fellow

Steven Corcelli, associate professor of chemistry and biochemistry, has been selected as a member of the 2016 Fellows of the American Chemical Society. The American Chemical Society (ACS) announced the news today in Chemical & Engineering News.

Read More

Collecting Compounds for the Treatment of Rare Genetic Disorders

Author: Brandi Klingerman

Richard Taylor

As Richard Taylor completes a three-year term as associate vice president for research in June of this year, he will continue his research on drug discovery for rare genetic diseases, like NGLY1 deficiency, when he and other members of the Warren Family Research Center for Drug Discovery and Development move into the building this summer. 

Read More

Understanding the Molecular Structure of Compounds in order to Advance Discovery of New Medicines and More

Author: Brandi Klingerman

At the University of Notre Dame, the Molecular Structure Facility (MSF) analyzes organic or inorganic substances at an atomic level, which allows researchers to learn about the three-dimensional structure and connectivity of the compound they have created. Knowing the molecular make-up of substances oftentimes provides faculty, postdoctoral fellows, and graduate students information about whether or not their substance is actually what was intended or even to see if their research is heading in the right direction.

Read More

Study reveals insights into protein linked to cancer and Alzheimer’s disease

Author: William G. Gilroy

NMR-based model for Pin1, and its interaction with its “disordered” protein targets pertinent to cancer and Alzheimer’s disease

Drugs to treat cancer and Alzheimer’s disease usually target the active sites of specific protein molecules sustaining the disease. Traditional drug design views proteins as rigid 3-D objects with active sites consisting of surface-accessible “pockets” with a specific, well-defined structure. Traditional drug design involves finding small molecules with shapes that fit specifically into this pocket. A new study from University of Notre Dame researchers suggests that there are alternative approaches to targeting these proteins, a significant finding for future clinical applications.

Read More

Helquist and Wiest receive US patent for HDAC inhibitors

Author: Gene Stowe

Olaf Wiest and Paul Helquist

Professors of chemistry and biochemistry, Paul Helquist and Olaf Wiest, together with Frederick Maxfield of Cornell University have received a U.S. patent for potential treatments for Niemann-Pick Type C (NPC) disease. Patent No. 9,333,222, “Histone deacetylase inhibitors as therapeutic agents for Niemann-Pick Type C Disease,” covers the full class of histone deacetylase inhibitors for the genetic, fatal lysosomal storage disorder and related diseases.

Read More